XANDRA
GARCÍA GONZÁLEZ
Profesora asociada de Ciencias de la Salud
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (8)
2021
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
2020
-
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine
Cancer Chemotherapy and Pharmacology, Vol. 86, Núm. 1, pp. 45-54
2019
2018
-
Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan
Pharmacological Research, Vol. 136, pp. 133-139
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
2017
-
Identification of new SNPs associated with severe toxicity to capecitabine
Pharmacological Research, Vol. 120, pp. 133-137
-
Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity
Pharmacogenomics, Vol. 18, Núm. 13, pp. 1215-1223
2015
-
Variants in CDA and ABCB1 are predictors of capecitabinerelated adverse reactions in colorectal cancer
Oncotarget, Vol. 6, Núm. 8, pp. 6422-6430